Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice.

Hdl Handle:
http://hdl.handle.net/10147/207627
Title:
Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice.
Authors:
Mumtaz, Aizad; FitzGerald, Oliver
Affiliation:
Bone and Joint Unit, Dublin Academic Health Care, St Vincent's University, Hospital, Elm Park, Dublin 4, Ireland.
Citation:
Curr Rheumatol Rep. 2010 Aug;12(4):264-71.
Journal:
Current rheumatology reports
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207627
DOI:
10.1007/s11926-010-0109-y
PubMed ID:
20440659
Abstract:
Psoriatic disease presents with a complex array of clinical features, including peripheral synovitis and skin psoriasis, but there is also variable involvement of the nail, dactylitis, enthesitis, and spinal disease. Composite assessment of disease activity and response taking into account the impact of the disease as a whole on an individual's health and quality of life is of vital importance. Following an extensive literature review, discussions, and consensus, the Group for Research in Psoriasis and Psoriatic Arthritis (GRAPPA) published guidelines to help clinicians make treatment decisions. The utility of these guidelines in routine clinical practice is further enhanced by incorporating them into a Composite Psoriatic Disease Activity Index (CPDAI). The potential application of the CPDAI in typical psoriatic disease patients is presented and discussed. Validation and possible modification of a composite disease activity and responder index is currently being undertaken by GRAPPA.
Language:
eng
MeSH:
Arthritis, Psoriatic/*therapy; Clinical Protocols; Humans; Severity of Illness Index
ISSN:
1534-6307 (Electronic); 1523-3774 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorMumtaz, Aizaden_GB
dc.contributor.authorFitzGerald, Oliveren_GB
dc.date.accessioned2012-02-01T10:33:17Z-
dc.date.available2012-02-01T10:33:17Z-
dc.date.issued2012-02-01T10:33:17Z-
dc.identifier.citationCurr Rheumatol Rep. 2010 Aug;12(4):264-71.en_GB
dc.identifier.issn1534-6307 (Electronic)en_GB
dc.identifier.issn1523-3774 (Linking)en_GB
dc.identifier.pmid20440659en_GB
dc.identifier.doi10.1007/s11926-010-0109-yen_GB
dc.identifier.urihttp://hdl.handle.net/10147/207627-
dc.description.abstractPsoriatic disease presents with a complex array of clinical features, including peripheral synovitis and skin psoriasis, but there is also variable involvement of the nail, dactylitis, enthesitis, and spinal disease. Composite assessment of disease activity and response taking into account the impact of the disease as a whole on an individual's health and quality of life is of vital importance. Following an extensive literature review, discussions, and consensus, the Group for Research in Psoriasis and Psoriatic Arthritis (GRAPPA) published guidelines to help clinicians make treatment decisions. The utility of these guidelines in routine clinical practice is further enhanced by incorporating them into a Composite Psoriatic Disease Activity Index (CPDAI). The potential application of the CPDAI in typical psoriatic disease patients is presented and discussed. Validation and possible modification of a composite disease activity and responder index is currently being undertaken by GRAPPA.en_GB
dc.language.isoengen_GB
dc.subject.meshArthritis, Psoriatic/*therapyen_GB
dc.subject.meshClinical Protocolsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshSeverity of Illness Indexen_GB
dc.titleApplication of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice.en_GB
dc.contributor.departmentBone and Joint Unit, Dublin Academic Health Care, St Vincent's University, Hospital, Elm Park, Dublin 4, Ireland.en_GB
dc.identifier.journalCurrent rheumatology reportsen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.